MCID: NDL021
MIFTS: 43

Nodular Lymphocyte Predominant Hodgkin Lymphoma

Categories: Cancer diseases, Blood diseases, Rare diseases, Immune diseases

Aliases & Classifications for Nodular Lymphocyte Predominant Hodgkin Lymphoma

MalaCards integrated aliases for Nodular Lymphocyte Predominant Hodgkin Lymphoma:

Name: Nodular Lymphocyte Predominant Hodgkin Lymphoma 56 69
Nlphl 56

Characteristics:

Orphanet epidemiological data:

56
nodular lymphocyte predominant hodgkin lymphoma
Prevalence: 1-9/1000000 (Worldwide),<1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:



Summaries for Nodular Lymphocyte Predominant Hodgkin Lymphoma

MalaCards based summary : Nodular Lymphocyte Predominant Hodgkin Lymphoma, also known as nlphl, is related to hemolytic anemia and hodgkin lymphoma, and has symptoms including hyperhidrosis, pruritus and splenomegaly. An important gene associated with Nodular Lymphocyte Predominant Hodgkin Lymphoma is BCL6 (B-Cell CLL/Lymphoma 6), and among its related pathways/superpathways are NF-kappaB Signaling and FoxO signaling pathway. The drugs Vinblastine and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone marrow, and related phenotypes are cellular and hematopoietic system

Related Diseases for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Diseases related to Nodular Lymphocyte Predominant Hodgkin Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 38)
id Related Disease Score Top Affiliating Genes
1 hemolytic anemia 28.9 IKZF1 PAX5
2 hodgkin lymphoma 12.0
3 lymphoma 11.0
4 b-cell lymphomas 10.5
5 hodgkin's granuloma 10.5
6 t-cell/histiocyte rich large b cell lymphoma 10.3
7 diffuse large b-cell lymphoma 10.3
8 pediatric lymphoma 10.2 BCL6 PAX5
9 ischemic optic neuropathy 10.2 BCL6 PAX5
10 primary malignant melanoma of the cervix 10.2 BCL6 PAX5
11 multiple congenital anomalies mental retardation, growth failure and cleft lip palate 10.2 BCL6 PAX5
12 spinal cord neuroblastoma 10.2 BCL6 PAX5
13 hepatoblastoma 10.2 BCL6 PAX5
14 villoglandular endometrial endometrioid adenocarcinoma 10.1 BCL6 PAX5
15 syngnathia cleft palate 10.1 BCL6 PAX5
16 hodgkin's lymphoma, lymphocytic-histiocytic predominance 10.1 BCL6 PAX5
17 peripheral t-cell lymphoma 10.0
18 ankyloglossia 10.0 IKZF1 PAX5
19 drug-induced hepatitis 10.0 BCL6 PAX5
20 seckel syndrome 10 9.9 BCL6 PAX5
21 carnitine-acylcarnitine translocase deficiency 9.9 BCL6 PAX5
22 kaposi sarcoma 9.9
23 li-fraumeni syndrome 9.9
24 hepatitis 9.9
25 sarcoma 9.9
26 leiomyoma 9.9
27 cervicitis 9.9
28 polyradiculopathy 9.9
29 adult lymphoma 9.9
30 thyroiditis 9.9
31 autoimmune hemolytic anemia 9.9
32 mediastinitis 9.9
33 progressive transformation of germinal centers 9.9
34 warthin tumor 9.9
35 primary mediastinal large b-cell lymphoma 9.9
36 preeclampsia/eclampsia 3 9.8 IKZF1 PAX5
37 bipolar disorder 9.8 BCL6 PAX5
38 vulvovaginal gingival syndrome 7.8 BCL6 IKZF1 PAX5 PDCD1 SGK1 VIM

Graphical network of the top 20 diseases related to Nodular Lymphocyte Predominant Hodgkin Lymphoma:



Diseases related to Nodular Lymphocyte Predominant Hodgkin Lymphoma

Symptoms & Phenotypes for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Human phenotypes related to Nodular Lymphocyte Predominant Hodgkin Lymphoma:

56 32 (show all 14)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hyperhidrosis 56 32 occasional (7.5%) Occasional (29-5%) HP:0000975
2 pruritus 56 32 occasional (7.5%) Occasional (29-5%) HP:0000989
3 splenomegaly 56 32 occasional (7.5%) Occasional (29-5%) HP:0001744
4 weight loss 56 32 occasional (7.5%) Occasional (29-5%) HP:0001824
5 fever 56 32 frequent (33%) Frequent (79-30%) HP:0001945
6 anorexia 56 32 occasional (7.5%) Occasional (29-5%) HP:0002039
7 hepatomegaly 56 32 occasional (7.5%) Occasional (29-5%) HP:0002240
8 lymphadenopathy 56 32 hallmark (90%) Very frequent (99-80%) HP:0002716
9 immunodeficiency 56 32 hallmark (90%) Very frequent (99-80%) HP:0002721
10 breast carcinoma 56 32 occasional (7.5%) Occasional (29-5%) HP:0003002
11 abnormality of bone marrow cell morphology 56 32 occasional (7.5%) Occasional (29-5%) HP:0005561
12 b-cell lymphoma 56 32 occasional (7.5%) Occasional (29-5%) HP:0012191
13 fatigue 56 32 occasional (7.5%) Occasional (29-5%) HP:0012378
14 lymphoma 56 Very frequent (99-80%)

MGI Mouse Phenotypes related to Nodular Lymphocyte Predominant Hodgkin Lymphoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.65 VIM BCL6 IKZF1 PAX5 PDCD1
2 hematopoietic system MP:0005397 9.55 VIM BCL6 IKZF1 PAX5 PDCD1
3 immune system MP:0005387 9.35 VIM BCL6 IKZF1 PAX5 PDCD1
4 respiratory system MP:0005388 8.92 VIM BCL6 IKZF1 PDCD1

Drugs & Therapeutics for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Drugs for Nodular Lymphocyte Predominant Hodgkin Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 90)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vinblastine Approved Phase 4,Phase 2 865-21-4 13342 241903
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3 50-18-0, 6055-19-2 2907
3
Prednisone Approved, Vet_approved Phase 4,Phase 3 53-03-2 5865
4
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
5
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
6 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
7 glucocorticoids Phase 4,Phase 3
8 Gastrointestinal Agents Phase 4,Phase 3
9 Hormone Antagonists Phase 4,Phase 3
10 Hormones Phase 4,Phase 3
11 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3
12 Peripheral Nervous System Agents Phase 4,Phase 3
13 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
14 Anti-Inflammatory Agents Phase 4,Phase 3
15 Antiemetics Phase 4,Phase 3
16 Autonomic Agents Phase 4,Phase 3
17 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Antimitotic Agents Phase 4,Phase 3,Phase 2
19 Antineoplastic Agents, Hormonal Phase 4,Phase 3
20 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2
21 Prednisolone acetate Phase 4
22 Methylprednisolone acetate Phase 4
23 Methylprednisolone Hemisuccinate Phase 4
24 Neuroprotective Agents Phase 4
25 Prednisolone hemisuccinate Phase 4
26 Prednisolone phosphate Phase 4
27 Protective Agents Phase 4
28
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
29
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
30
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
31
Etoposide Approved Phase 3 33419-42-0 36462
32
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
33
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
34
Vinorelbine Approved, Investigational Phase 3,Phase 2 71486-22-1 60780 44424639
35
Bleomycin Approved Phase 3 11056-06-7 5360373
36
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
37
Mechlorethamine Approved Phase 3,Phase 2 51-75-2 4033
38
Lenograstim Approved Phase 3,Phase 2 135968-09-1
39
Cortisone acetate Approved Phase 3 1950-04-4, 50-04-4 5745
40
Doxil Approved June 1999 Phase 3,Phase 2 31703
41 Podophyllotoxin Phase 3 518-28-5
42
Cortisone Phase 3 53-06-5 222786
43 Dexamethasone acetate Phase 3 1177-87-3
44 Isophosphamide mustard Phase 3,Phase 2
45
protease inhibitors Phase 3
46 Adjuvants, Immunologic Phase 3,Phase 2
47 HIV Protease Inhibitors Phase 3
48 Topoisomerase Inhibitors Phase 3,Phase 2
49 Dermatologic Agents Phase 3
50 Ophthalmic Solutions Phase 3

Interventional clinical trials:

(show all 18)

id Name Status NCT ID Phase Drugs
1 Surgery Alone, Surgery With Cyclophosphamide, Vinblastine, and Prednisolone (CVP), or CVP Alone in Treating Young Patients With Stage IA or Stage IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma Recruiting NCT01088750 Phase 4 cyclophosphamide;prednisolone;vinblastine sulfate
2 Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma Completed NCT01026220 Phase 3 doxorubicin hydrochloride;liposomal vincristine sulfate;vinorelbine tartrate;cyclophosphamide;etoposide phosphate;prednisone;ifosfamide
3 Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease Completed NCT00025259 Phase 3 Cisplatin;Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Prednisone;Vincristine Sulfate Liposome
4 Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) Completed NCT01187303 Phase 2 Ofatumumab
5 Rituximab in Treating Patients With Hodgkin's Lymphoma Completed NCT00003820 Phase 2 Rituximab
6 A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma Completed NCT01460940 Phase 2 panobinostat;lenalidomide
7 Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy Completed NCT00381940 Phase 2 ifosfamide;bortezomib;vinorelbine tartrate
8 Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma Completed NCT00132028 Phase 2 vorinostat
9 Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment. Completed NCT01022996 Phase 2 Everolimus (RAD001)
10 SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Completed NCT00337194 Phase 2 vinorelbine tartrate;pegylated liposomal doxorubicin hydrochloride;gemcitabine hydrochloride
11 Combination Chemotherapy in Treating Children With Refractory or Relapsed Hodgkin's Lymphoma Completed NCT00006760 Phase 2 ifosfamide;vinorelbine tartrate
12 Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL) Recruiting NCT02626884 Phase 2 Ibrutinib
13 Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma Active, not recruiting NCT01535924 Phase 1, Phase 2 gemcitabine hydrochloride;bendamustine hydrochloride
14 Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma Terminated NCT00288067 Phase 1, Phase 2 fenretinide;rituximab
15 Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment Withdrawn NCT00881387 Phase 2 gemcitabine hydrochloride;vinorelbine ditartrate
16 Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma Completed NCT01273090 Phase 1 imetelstat sodium
17 Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant Active, not recruiting NCT01588015 Phase 1
18 Protein Biomarker Levels in Tissue Samples From Young Patients With Low-risk Hodgkin Lymphoma Completed NCT01366157

Search NIH Clinical Center for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Genetic Tests for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Anatomical Context for Nodular Lymphocyte Predominant Hodgkin Lymphoma

MalaCards organs/tissues related to Nodular Lymphocyte Predominant Hodgkin Lymphoma:

39
B Cells, T Cells, Bone Marrow, Bone, Breast, Lymph Node, Monocytes

Publications for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Articles related to Nodular Lymphocyte Predominant Hodgkin Lymphoma:

(show top 50) (show all 145)
id Title Authors Year
1
Rituximab in a risk-adapted treatment strategy gives excellent therapeutic results in nodular lymphocyte-predominant Hodgkin lymphoma. ( 28737231 )
2017
2
Nodular lymphocyte predominant Hodgkin lymphoma in USA between 2000 and 2014: an updated analysis based on the SEER data. ( 28737250 )
2017
3
Variant histology, IgD and CD30 expression in low-risk pediatric nodular lymphocyte predominant Hodgkin lymphoma: A report from the Children's Oncology Group. ( 28802087 )
2017
4
Variant histology nodular lymphocyte predominant Hodgkin lymphoma - a route to transformation? ( 28369705 )
2017
5
Encouraging activity for R-CHOP in Advanced Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma. ( 28522441 )
2017
6
J chain and myocyte enhancer factor 2B are useful in differentiating classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. ( 28851661 )
2017
7
Advanced stage nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents: clinical characteristics and treatment outcome - a report from the SFCE & CCLG groups. ( 28220934 )
2017
8
Nodular Lymphocyte-predominant Hodgkin Lymphoma in a 15-Year-Old Boy With Li-Fraumeni Syndrome Having a Germline TP53 D49H Mutation. ( 28902083 )
2017
9
Nodular Lymphocyte Predominant Hodgkin Lymphoma: A Real-world Case Series of Consecutive Patients Treated by a Single Multidisciplinary Team in the East of England From 1999 to 2015. ( 28935378 )
2017
10
Nodular lymphocyte predominant Hodgkin lymphoma in Sweden between 2000 and 2014: an analysis of the Swedish Lymphoma Registry. ( 28233899 )
2017
11
T-cell rosettes in nodular lymphocyte-predominant Hodgkin lymphoma. ( 28183747 )
2017
12
GATA3 Immunohistochemical Staining in Hodgkin Lymphoma: Diagnostic Utility in Differentiating Classic Hodgkin Lymphoma From Nodular Lymphocyte Predominant Hodgkin Lymphoma and Other Mimicking Entities. ( 28877074 )
2017
13
Cyclin D1 expression and polysomy in lymphocyte-predominant cells of nodular lymphocyte-predominant Hodgkin lymphoma. ( 28038705 )
2017
14
Characterization and Purification of Neoplastic Cells of Nodular Lymphocyte Predominant Hodgkin Lymphoma from Lymph Nodes by Flow Cytometry and Flow Cytometric Cell Sorting. ( 27998726 )
2017
15
Characterization of the Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma. ( 27999289 )
2016
16
A strong host response and lack of MYC expression are characteristic for diffuse large B cell lymphoma transformed from nodular lymphocyte predominant Hodgkin lymphoma. ( 27708232 )
2016
17
Nodular lymphocyte-predominant Hodgkin lymphoma. ( 27496311 )
2016
18
The role of tumour-infiltrating eosinophils, mast cells and macrophages in Classical and Nodular Lymphocyte Predominant Hodgkin Lymphoma in children. ( 26872637 )
2016
19
Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma. ( 26658840 )
2016
20
Nodular Lymphocyte Predominant Hodgkin Lymphoma Presenting with Unilateral Orbital Involvement. ( 27015240 )
2016
21
A 20-year population-based study on the epidemiology, clinical features, treatment, and outcome of nodular lymphocyte predominant Hodgkin lymphoma. ( 26732883 )
2016
22
Complete remission following lenalidomide and rituximab in a patient with heavily pretreated nodular lymphocyte predominant Hodgkin lymphoma. ( 26762971 )
2016
23
Diagnostic Utility of Flow Cytometry Analysis of Reactive T Cells in Nodular Lymphocyte-Predominant Hodgkin Lymphoma. ( 26712878 )
2016
24
Nodular Lymphocyte Predominant Hodgkin Lymphoma of the Thyroid. ( 28044111 )
2016
25
An unusual clinical and pathological presentation of a nodular lymphocyte predominant Hodgkin lymphoma ("Poppema Lennert" lymphoma). ( 27532537 )
2016
26
A case of composite classical and nodular lymphocyte predominant Hodgkin lymphoma with progression to diffuse large B-cell non-Hodgkin lymphoma: Diagnostic difficulty in fine-needle aspiration cytology. ( 27888658 )
2016
27
Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution. ( 26837698 )
2016
28
Rituximab plus ABVD in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma. ( 26913966 )
2016
29
Relapsed or poorly responsive nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents - a report from the United Kingdom's Children's Cancer and Leukaemia Study Group. ( 26996288 )
2016
30
Atypical variants of nodular lymphocyte predominant Hodgkin lymphoma show low microvessel density and vessels of distention type. ( 27816718 )
2016
31
Intraparotid classical and nodular lymphocyte-predominant Hodgkin lymphoma: pattern analysis with emphasis on associated lymphadenoma-like proliferations. ( 25929348 )
2015
32
Childhood and Adolescent nodular lymphocyte predominant Hodgkin lymphoma - A review of clinical outcome based on the histological variants. ( 26115355 )
2015
33
Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study. ( 26430172 )
2015
34
Guidelines for the investigation and management of nodular lymphocyte predominant Hodgkin lymphoma. ( 26538004 )
2015
35
What Is the Role of Rituximab in Nodular Lymphocyte-Predominant Hodgkin Lymphoma? ( 26022927 )
2015
36
CD57+ T-cells are a subpopulation of T-follicular helper cells in nodular lymphocyte predominant Hodgkin lymphoma. ( 26380151 )
2015
37
Race-specific features and outcomes of nodular lymphocyte-predominant Hodgkin lymphoma: Analysis of the National Cancer Data Base. ( 26149294 )
2015
38
Nodular Lymphocyte-Predominant Hodgkin Lymphoma in a Warthin Tumor of the Parotid Gland: A Case Report and Literature Review. ( 26169920 )
2015
39
Immunoarchitectural patterns in nodular lymphocyte predominant Hodgkin lymphoma: pathologic and clinical implications. ( 25487651 )
2015
40
Primary nodular lymphocyte-predominant Hodgkin lymphoma of uterine cervix mimicking leiomyoma. ( 26185626 )
2015
41
Incidence, management and outcome of high grade transformation of nodular lymphocyte predominant Hodgkin lymphoma: long-term outcomes from a 30-year experience. ( 25715900 )
2015
42
XVIII. Management of nodular lymphocyte predominant Hodgkin lymphoma. ( 26062064 )
2015
43
High-dose chemotherapy and autologous stem cell transplantation for relapsed or refractory nodular lymphocyte predominant Hodgkin lymphoma. ( 26467917 )
2015
44
Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group. ( 26585412 )
2015
45
Early-stage nodular lymphocyte-predominant Hodgkin lymphoma: the impact of radiotherapy on overall survival. ( 26110882 )
2015
46
Identifying racial differences in nodular lymphocyte-predominant Hodgkin lymphoma. ( 26149195 )
2015
47
Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group. ( 26240235 )
2015
48
Lymphocyte-Rich Classical Hodgkin Lymphoma. A Case with Difficulty in Distinguishing from Nodular Lymphocyte-Predominant Hodgkin Lymphoma. ( 26106003 )
2015
49
Rituximab-ABV(D) for patients with Nodular lymphocyte predominant Hodgkin lymphoma ineligible for radiation therapy. ( 26685097 )
2015
50
Array comparative genomic hybridization reveals similarities between nodular lymphocyte predominant Hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma. ( 25644177 )
2015

Variations for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Expression for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Search GEO for disease gene expression data for Nodular Lymphocyte Predominant Hodgkin Lymphoma.

Pathways for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Pathways related to Nodular Lymphocyte Predominant Hodgkin Lymphoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.95 BCL6 IKZF1 PAX5 PDCD1
2
Show member pathways
11.54 BCL6 SGK1
3 11.43 BCL6 VIM
4 11.11 BCL6 SGK1
5 10.98 BCL6 PAX5 PDCD1
6 10.94 BCL6 SGK1
7 10.52 BCL6 PAX5 PDCD1

GO Terms for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Biological processes related to Nodular Lymphocyte Predominant Hodgkin Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 humoral immune response GO:0006959 8.62 PAX5 PDCD1

Sources for Nodular Lymphocyte Predominant Hodgkin Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....